总结2021年提交给Hematopathology协会和欧洲血液病理协会研讨会的病例归为霍奇金淋巴瘤、浆细胞成型瘤和浆细胞骨髓瘤三类。该研讨会小组审核了20个在本次会议上涵盖的病例。此外，对提交的10个病例进行了全外显子组测序和全基因组RNA表达分析，包括6个霍奇金淋巴瘤和4个浆液肿瘤。霍奇金淋巴瘤的病例包括转化为或自各种B细胞淋巴瘤转化而来的病例，仅有1个例外，其发生了T细胞分化。浆液肿瘤的病例包括浆母细胞进展、进展为浆细胞白血病和继发性B淋巴母细胞白血病的病例。WES鉴定的基因变异包括一些在霍奇金淋巴瘤和浆液肿瘤中已知的经常性变异。提交的所有霍奇金淋巴瘤样本都显示出了这些突变中的一个或更多：SOCS1、FGFR2、KMT2D、RIT1、SPEN、STAT6、TET2、TNFAIP3和ZNF217。这两种肿瘤的更好分子特征和进展机制的表征将帮助我们更好地了解进展机制，也许可以开发更好的预后模型，并确定新的治疗靶点。 © 作者2023。由牛津大学出版社代表美国临床病理学会出版。版权所有。有关权限，请发送电子邮件至：journals.permissions@oup.com。

To summarize cases submitted to the 2021 Society for Hematopathology/European Association for Haematopathology Workshop under the categories of progression of Hodgkin lymphoma, plasmablastic myeloma, and plasma cell myeloma.The workshop panel reviewed 20 cases covered in this session. In addition, whole-exome sequencing (WES) and whole-genome RNA expression analysis were performed on 10 submitted cases, including 6 Hodgkin lymphoma and 4 plasma neoplasm cases.The cases of Hodgkin lymphoma included transformed cases to or from various types of B-cell lymphoma with 1 exception, which had T-cell differentiation. The cases of plasma cell neoplasms included cases with plasmablastic progression, progression to plasma cell leukemia, and secondary B-lymphoblastic leukemia. Gene variants identified by WES included some known to be recurrent in Hodgkin lymphoma and plasma cell neoplasm. All submitted Hodgkin lymphoma samples showed 1 or more of these mutations: SOCS1, FGFR2, KMT2D, RIT1, SPEN, STAT6, TET2, TNFAIP3, and ZNF217.Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.© The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.